Key result
Clearance-driven hypocholesterolemia is cardioprotective without liver harm, while impaired hepatic secretion increases liver disease risk.
Why the study?
Although hypocholesterolemia is perceived as benign due to lower cardiovascular risk, persistently low LDL-C and ApoB arise from distinct biological mechanisms with divergent hepatic implications.
Comparison
Secretion-driven vs clearance-driven hypocholesterolemia
Design
Review
Authors
Loading...
Caution against assuming hypocholesterolemia is benign without mechanism; leaves open distinct hepatic risks for prospective study.
The clinical consequences of hypocholesterolemia are determined by its underlying biological mechanism (impaired secretion vs. enhanced clearance), which should guide the need for liver disease monitoring.
Flagiello et al. (2026) conducted a review in Hypocholesterolemia and metabolic dysfunction-associated steatotic liver disease (MASLD). Genetic hypocholesterolemia was evaluated. Hypocholesterolemia driven by impaired hepatic secretion increases liver disease risk, whereas clearance-driven hypocholesterolemia is cardioprotective without adverse hepatic outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: